Biliary Tract Cancer New Reference: Erdafitinib for Advanced Solid Tumors with FGFR Alterations Ulas D. Bayraktar, MD 2023-09-23
Non-Small Cell Lung Cancer New Indication: Trastuzumab Deruxtecan for her2 Mutant NSCLC Ulas D. Bayraktar, MD 2023-09-23
Uterine Cancer New Indication: Selinexor for Maintenance in Advanced Endometrial Cancer Ulas D. Bayraktar, MD 2023-09-23
Colorectal Cancer New Indication: Avelumab for MSI-High Metastatic Colorectal Cancer Ulas D. Bayraktar, MD 2023-08-20
Diffuse Large B Cell Lymphoma New Drug: Glofitamab in Large B-Cell Lymphoma Ulas D. Bayraktar, MD 2023-08-20
GastroEsophageal Cancer New Reference: Trastuzumab Deruxtecan in her2-Positive Advanced Gastroesophageal Cancer Ulas D. Bayraktar, MD 2023-08-20
Non-Small Cell Lung Cancer New Indication: Pembrolizumab for Early-Stage NSCLC Ulas D. Bayraktar, MD 2023-08-20
Non-Small Cell Lung Cancer New Indication: Perioperative Nivolumab and Chemotherapy for Stage III NSCLC Ulas D. Bayraktar, MD 2023-08-20
Uterine Cancer New Protocol: Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma Ulas D. Bayraktar, MD 2023-08-20
Renal Cell Carcinoma New Reference: Pembrolizumab and Lenvatinib for Advanced Non-Clear-Cell RCC Ulas D. Bayraktar, MD 2023-08-20
